Lack of Transparency in Commercialization

Another issue is the lack of transparency in how strain IP is commercialized.

Once a new strain is developed, it often passes through private contracts or licensing deals that are opaque to outsiders.

Growers and dispensaries must pay high fees without any clear breakdown of how revenues flow back to the breeding process.

This system sidelines community involvement and prevents shared economic growth from what has become a multi-billion dollar global industry.